What Is SS-31?

Overview

SS-31 (elamipretide) is a synthetic, aromatic-cationic tetrapeptide belonging to the Szeto-Schiller (SS) family of mitochondria-targeted peptides. Its sequence — D-Arg-Dmt-Lys-Phe-NH₂ — alternates cationic residues (D-Arg, Lys) with aromatic residues (Dmt, Phe), an architectural pattern that confers selective, high-affinity binding to cardiolipin (CL) on the inner mitochondrial membrane (IMM).[1][2]

Discovery: SS-31 was identified serendipitously by Dr. Hazel Szeto (Weill Cornell Medical College) and Dr. Peter Schiller (Montreal IRCM) during research into opioid receptor agonists. It was derived from SS-02 ([Dmt¹]DALDA), a synthetic opioid peptide analog, but engineered to completely eliminate opioid receptor activity while retaining the aromatic-cationic motif required for mitochondrial targeting.[1]

Key distinguishing features: (1) Concentrates 5,000-fold in the IMM via cardiolipin binding; (2) Uptake is membrane-potential-independent (unlike MitoQ, which requires intact electrochemical gradient); (3) Has no effect on healthy mitochondria — improves bioenergetics only in aged/dysfunctional mitochondria; (4) Small, water-soluble, crosses the blood-brain barrier.[2][4]

Regulatory milestone: On September 19, 2025, the FDA granted Accelerated Approval to Forzinity™ (elamipretide) for Barth syndrome — a rare genetic disorder caused by TAFAZZIN gene mutations leading to cardiolipin deficiency. This made SS-31 the first drug ever authorized by the FDA specifically for Barth syndrome, and one of the first mitochondrially-targeted drugs to receive FDA approval for any indication.[3]

Compared to MOTS-c — another mitochondria-targeted research compound — SS-31 acts upstream at the level of cardiolipin and the electron transport chain itself, rather than via nuclear gene regulation.[1]

Discovery and design rationale

SS-31 was identified by Szeto and Schiller during structure-activity dissection of opioid-receptor agonists derived from [Dmt¹]DALDA (SS-02), a synthetic δ-opioid peptide analog originally explored as an analgesic scaffold. During radiolabeled distribution studies the parent SS-02 was unexpectedly observed to concentrate inside isolated mitochondria far more than predicted by its opioid-receptor distribution profile. Iterative residue substitution preserved the alternating aromatic-cationic-aromatic-cationic motif (D-Arg-Dmt-Lys-Phe-NH₂) needed for cardiolipin engagement while D-amino acid stereochemistry and N-methylation eliminated detectable affinity for μ-, δ-, and κ-opioid receptors in radioligand binding assays.[1] The redesign converted an off-target observation in opioid pharmacology into the founding member of the Szeto-Schiller (SS) class of mitochondria-targeted research peptides.

Research framework

Within the broader mitochondrial-bioenergetics research-peptide family, SS-31 is most directly compared with MOTS-c (a 16-amino-acid mitochondrial-derived peptide acting on the AMPK / Nrf2 / folate-cycle axis), NAD+ precursors (which raise mitochondrial NAD+ pools to support sirtuin and Complex I function), and glutathione (a cytosolic/matrix tripeptide antioxidant). SS-31 is the only member of this comparison set that engages the inner mitochondrial membrane lipid bilayer itself rather than a soluble cofactor pool or a nuclear gene-expression program — making it the appropriate research tool when investigators are isolating cardiolipin-dependent ETC architecture from nuclear-encoded mitochondrial biogenesis pathways.[2][4]